Sermorelin is the native N-terminal 29-amino acid bioactive fragment of human Growth Hormone-Releasing Hormone (GHRH 1–29), serving as the physiological short-half-life benchmark against modified analogues like CJC-1295.
Scientific Profile & Research Key Points: Sermorelin
Sermorelin is the native N-terminal 29-amino acid bioactive fragment of human Growth Hormone-Releasing Hormone (GHRH 1–29), serving as the physiological short-half-life benchmark against modified analogues like CJC-1295.
Active Batch Release Specifications (Lot SL-2026-156)
Analytical release verification for current Sermorelin (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-156 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (1.0–2.0 mL)
Temperature & Stability
Store lyophilized at -20°C; refrigerate solution at 2°C–8°C for up to 21 days.
Sermorelin — Technical Questions & Answers
What is the molar concentration when reconstituting Sermorelin (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of Sermorelin (MW 3357.88 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 0.74 mM (745 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Sermorelin's counterion stoichiometry affect assay mass calculations?
Sermorelin (CAS 86168-78-7, formula C149H246N44O42S) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Sermorelin Lot SL-2026-156 and what pathway does it target?
Lot SL-2026-156 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 3357.88 g/mol. In preclinical literature, Sermorelin targets Pituitary GHRH Receptor (native short-acting reference ligand) (Prakash A. & Goa K.L., BioDrugs (1999) — Sermorelin pharmacology and pituitary GHRH receptor dynamics (PMID: 18031173)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
CJC-1295, Ipamorelin, and Sermorelin: GHRH Analogues vs Ghrelin Receptor Agonists
A deep dive into somatotropic axis stimulation. Comparing GHRH receptor binding, DAC modification kinetics, ghrelin/GHS-R1a agonism, and pulsatile growth hormone secretion.
Gonadorelin, HCG, HMG and Kisspeptin: Mapping the Hypothalamic-Pituitary-Gonadal Axis
A comparative map of the HPG axis: GnRH receptor agonism (Gonadorelin), LH receptor mimetics (HCG), combined FSH/LH activity (HMG), and upstream GPR54 activation (Kisspeptin-10).
Human Growth Hormone (191aa): Somatropin Structure, Isoforms, and SEC-HPLC Analysis
A deep analysis of authentic 191-amino acid Somatropin vs 192-amino acid Somatrem. Size-exclusion chromatography (SEC), deamidation artifacts, and mass confirmation.
Related GH Secretagogues & Growth Factors Compounds
View category →